Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

46461

Supelco

Metronidazole

VETRANAL®, analytical standard

Synonyme(s) :

2-Methyl-5-nitroimidazole-1-ethanol

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C6H9N3O3
Numéro CAS:
443-48-1
Poids moléculaire :
171.15
Beilstein:
611683
Numéro CE :
207-136-1
Numéro MDL:
MFCD00009750
Code UNSPSC :
41116107
ID de substance PubChem :
329757194
Nomenclature NACRES :
NA.24

Qualité

analytical standard

Niveau de qualité

200

Gamme de produits

VETRANAL®

Durée de conservation

limited shelf life, expiry date on the label

Technique(s)

HPLC: suitable
gas chromatography (GC): suitable

Pf

159-161 °C (lit.)

Spectre d'activité de l'antibiotique

Gram-negative bacteria
parasites

Application(s)

clinical testing

Format

neat

Mode d’action

DNA synthesis | interferes

Température de stockage

2-8°C

Chaîne SMILES 

CC1=NC=C([N+]([O-])=O)N1CCO

InChI

1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3

Clé InChI

VAOCPAMSLUNLGC-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Chemical structure: imidazole

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Produits recommandés

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

Informations légales

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H340,H350,H373

Classification des risques

Carc. 1B - Muta. 1B - STOT RE 2

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Gloves

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
BCCJ4839
BCCG8315
BCCB0355
BCBX3839
BCBW4436

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 7

1 of 7

Ronidazole-d3 VETRANAL®, analytical standard

Supelco

34217

Ronidazole-d3

Ronidazole analytical standard

Supelco

R7635

Ronidazole

Mebendazole analytical standard, ≥98% (HPLC)

Supelco

M2523

Mebendazole

Metronidazole impurity A European Pharmacopoeia (EP) Reference Standard

Y0000087

Metronidazole impurity A

Triméthoprime VETRANAL®, analytical standard

Supelco

46984

Triméthoprime

vibrant-m

M1851000

Metronidazole benzoate

Dicloxacillin sodium salt hydrate VETRANAL®, analytical standard

Supelco

46182

Dicloxacillin sodium salt hydrate

Sonja Löfmark et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 50 Suppl 1, S16-S23 (2010-01-14)
Metronidazole has been used for the treatment of infections for >45 years and is still successfully used for the treatment of trichomoniasis, amoebiasis, and giardiasis. Anaerobic bacterial infections caused by Bacteroides species, fusobacteria, and clostridia respond favorably to metronidazole therapy.
Konstantinos Z Vardakas et al.
International journal of antimicrobial agents, 40(1), 1-8 (2012-03-09)
The objective of this review was to evaluate the frequency of treatment failure and recurrence of Clostridium difficile infection (CDI) following treatment with vancomycin or metronidazole in recently performed studies (last 10 years). Searches in PubMed and Scopus were performed
T H I Brummer et al.
BJOG : an international journal of obstetrics and gynaecology, 120(10), 1269-1276 (2013-06-22)
To evaluate cefuroxime and metronidazole antibiotic prophylaxis. Observational nonrandomised 1-year prospective cohort study. Fifty-three hospitals in Finland. A total of 5279 women undergoing hysterectomy for benign indications, with cefuroxime given to 4301 and metronidazole given to 2855. Excluding other antibiotics
Christina M Surawicz et al.
The American journal of gastroenterology, 108(4), 478-498 (2013-02-27)
Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system. Patients with CDI typically have extended lengths-of-stay in hospitals, and CDI is a frequent cause of large hospital outbreaks
Amber Howerton et al.
The Journal of infectious diseases, 207(10), 1498-1504 (2013-02-20)
Clostridium difficile infection (CDI) is a leading cause of antibiotic-associated diarrhea. The infective form of C. difficile is the spore, but the vegetative bacterium causes the disease. Because C. difficile spore germination is required for symptomatic infection, antigermination approaches could
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique